Aptose Biosciences Inc. (NASDAQ:APTO) Sees Significant Decline in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 54,900 shares, a decline of 35.9% from the March 31st total of 85,600 shares. Based on an average daily volume of 93,500 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.6% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on APTO shares. Piper Sandler reaffirmed an “overweight” rating and set a $5.00 target price on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Aptose Biosciences in a report on Wednesday, March 27th. Finally, StockNews.com upgraded shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, March 28th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.80.

Institutional Investors Weigh In On Aptose Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of APTO. Texas Capital Bank Wealth Management Services Inc bought a new stake in Aptose Biosciences in the 4th quarter valued at about $32,000. Annandale Capital LLC grew its position in Aptose Biosciences by 40.0% in the 3rd quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 21,334 shares during the period. Finally, Sigma Planning Corp acquired a new position in Aptose Biosciences during the third quarter worth $408,000. 26.62% of the stock is owned by institutional investors.

Aptose Biosciences Stock Up 5.2 %

Shares of Aptose Biosciences stock traded up $0.06 on Friday, hitting $1.22. 104,878 shares of the company’s stock traded hands, compared to its average volume of 68,246. The company has a fifty day moving average of $1.54 and a two-hundred day moving average of $2.11. Aptose Biosciences has a one year low of $1.15 and a one year high of $8.70.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings data on Tuesday, March 26th. The biotechnology company reported ($1.44) EPS for the quarter, topping the consensus estimate of ($1.48) by $0.04. Equities research analysts anticipate that Aptose Biosciences will post -3.31 EPS for the current year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.